Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer

Figure 3 Augmented growth inhibition of combination treatment with NVP-AEW541 plus either 5-FU (A), or SN-38 (B) or cetuximab (C) (mean ± SE, n = 4-6). A: Combination treatment with sub-IC₅₀ concentrations of NVP-AEW541 plus 5-FU led to synergistic growth inhibition of colorectal cancer cells; B: Combination treatment with sub-IC₅₀ concentrations of NVP-AEW541 plus the humanized EGFR-antibody cetuximab resulted in slightly over-additive antiprolifertive effects; C: Co-treatment with sub-IC₅₀ concentrations of NVP-AEW541 and SN-38 resulted in additive growth inhibition of HCT-116 cells, while no additive growth inhibition was detected in HT-29 cells. Black bars indicate the values of the calculated additive growth inhibition. Data are given as percentage of untreated controls.